000			03527cam a2200349 a 4500
003			EG-GiCUC
005			20250223031559.0
008			161019s2016 ua dh f m 000 0 eng d
040			_aEG-GiCUC _beng _cEG-GiCUC
041	0		_aeng
049			_aDeposite
097			_aM.Sc
099			_aCai01.11.28.M.Sc.2016.At.B
100	0		_aAthar Marwan Abdelaliem Ibrahim
245	1	0	_aBone metabolism and turnover markers in children with steroid-dependant \ frequently-relapsing and steroid- resistant nephrotic syndrome / _cAthar Marwan Abdelaliem Ibrahim ; Supervised Emad Emil Ghobrial , Hanan Abdelaziz Ahmed , Riham Elsayed Hanafy
246	1	5	_aعلامات التغير فى مكونات العظام لأطفال المصابين بالمتلازمة النفروزية المعتمدة على العلاج والغير مستجيبة للعلاج - بالكورتيزون
260			_aCairo : _bAthar Marwan Abdelaliem Ibrahim , _c2016
300			_a122 P. : _bcharts , facsimiles ; _c25cm
502			_aThesis (M.Sc.) - Cairo University - Faculty of Medicine - Department of Pediatrics
520			_aBackground: Children with nephrotic syndrome may be at risk for metabolic bone disease because of biochemical derangement caused by renal disease as well as steroid therapy. Objectives: The aim of the work was to evaluate linear growth and bone turnover markers (Calcium, Phosphorus, Alkaline phosphatase and Osteocalcin) in nephrotic syndrome patients specially SDNS{u2215}FRNS and SRNS patients in comparison to a matched control group. Methods: The study is a cross sectional case-control study that included 30 patients with SDNS{u2215}FRNS and 30 SRNS patients aged 2-15 years matched with 28 healthy control children. Both patients and controls was subjected to clinical examination and we measured serum calcium, phosphorus, alkaline phosphatase and osteocalcin). Results: Height of both SDNS{u2215}FRNS and SRNS showed lower height for age percentile compared to control group (p=0.017 and 0.00 respectively). Also height of all NS patients were negatively correlated to duration of steroid, cyclophosphamide (CYP) and cyclosporine therapy (p= 0.05, p= 0.044 and 0.02 respectively).Lower serum calcium levels were (mean 8.9±0.8) mg/dL and significant lower calcium levels in all NS patients compared to the control group (P=0.0001). Higher ALP levels in both SDNS{u2215}FRNS and SRNS patients compared to control group but with statistical significance for only SRNS patients (p= 0.02). Higher Serum osteocalcin levels in both SDNS{u2215}FRNS and SRNS patients groups compared to the control group (P=0.02 and 0.01 respectively). We also found that osteocalcin levels were negatively correlated to serum calcium levels of our patients (p-value = 0.0001). Conclusion: Glucocorticoids therapy of NS patients especially on long term treatment in SDNS{u2215}FRNS and SRNS patients affects the height of patients and some markers of bone metabolism in the form of decrease serum Calcium level and increase serum alkaline phosphatase and osteocalcin level
530			_aIssued also as CD
653		4	_aFrequently-Relapsing and steroid
653		4	_aResistant nephrotic Syndrome
653		4	_aSteroid-Dependant
700	0		_aEmad Emil Ghobrial , _eSupervisor
700	0		_aHanan Abdelaziz Ahmed , _eSupervisor
700	0		_aRiham Elsayed Hanafy , _eSupervisor
856			_uhttp://172.23.153.220/th.pdf
905			_aNazla _eRevisor
905			_aSamah _eCataloger
942			_2ddc _cTH
999			_c58191 _d58191